Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06459921
Study type Interventional
Source Xijing Hospital
Contact Jipeng Li, Doctor
Phone 13991316190
Email jipeng1974@aliyun.com
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2024
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Active, not recruiting NCT03719833 - Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Not yet recruiting NCT04384601 - Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer Phase 3
Recruiting NCT04576143 - Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer Phase 2/Phase 3
Not yet recruiting NCT03688035 - Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Recruiting NCT03493880 - The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Completed NCT06149884 - Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
Recruiting NCT03715686 - To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes N/A
Recruiting NCT03750669 - Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05522985 - Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT03349177 - Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Phase 2/Phase 3
Terminated NCT03585062 - Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer Phase 2
Enrolling by invitation NCT06120309 - New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
Recruiting NCT04004559 - MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
Recruiting NCT04047693 - Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma Phase 2
Recruiting NCT06220214 - Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer Early Phase 1
Recruiting NCT05910710 - Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Suspended NCT05503108 - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Phase 3
Recruiting NCT05367206 - Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial Phase 3